TABLE 1.
Baseline clinical characteristics of patients.
| Characteristic | Total n (%) | RT group n (%) | NRT group n (%) | p‐value |
|---|---|---|---|---|
| Patients, n (%) | 82 | 42 (51.2) | 40 (48.8) | ‐ |
| Age, median (range) | 56 (27–75) | 58 (27–75) | 55 (34–71) | 0.57 |
| Sex | 0.65 | |||
| Male | 39 (47.6) | 21 (50.0) | 18 (45.0) | |
| Female | 43 (52.4) | 21 (50.0) | 22 (55.0) | |
| ECOG PS | 0.78 | |||
| 0 | 32 (39.0) | 17 (40.5) | 15 (37.5) | |
| 1 | 50 (61.0) | 25 (59.5) | 25 (62.5) | |
| Cancer type | 0.26 | |||
| Primary metastatic disease | 44 (53.7) | 20 (47.6) | 24 (60.0) | |
| Recurrent metastatic disease | 38 (46.3) | 22 (52.4) | 16 (40.0) | |
| Primary tumor location | 0.54 | |||
| Rectum | 32 (39.0) | 18 (42.9) | 14 (35.0) | |
| Left colon | 24 (29.3) | 13 (31.0) | 11 (27.5) | |
| Right colon | 26 (31.7) | 11 (26.2) | 15 (37.5) | |
| Metastases location | ||||
| Liver | 50 (61.0) | 27 (64.3) | 23 (57.5) | 0.53 |
| Lung | 50 (61.0) | 30 (71.4) | 20 (50.0) | 0.05 |
| Peritoneum | 15 (18.3) | 7 (16.7) | 8 (20.0) | 0.70 |
| Lymph node | 38 (46.3) | 17 (40.5) | 21 (52.2) | 0.28 |
| Numbers of metastatic oragns | 0.32 | |||
| 1 site | 13 (15.9) | 5 (11.9) | 8 (20.0) | |
| ≥2 sites | 69 (84.1) | 37 (88.1) | 32 (80.0) | |
| Prior regimens | ||||
| 5‐fluorouracil | 82 (100) | 42 (100) | 40 (100) | ‐ |
| Oxaliplatin | 80 (97.6) | 41 (97.6) | 39 (97.5) | 1 a |
| Irinotecan | 79 (96.3) | 41 (97.6) | 38 (95.0) | 0.61 a |
| Bevacizumab | 70 (85.4) | 35 (83.3) | 35 (87.5) | 0.59 |
| Cetuximab | 20 (24.4) | 10 (23.8) | 10 (25.0) | 0.90 |
| Regorafenib | 4 (4.9) | 1 (2.4) | 3 (7.5) | 0.35 a |
| Fruquintinib | 6 (7.3) | 3 (7.1) | 3 (7.5) | 1 a |
| Primary lesion excision | 0.34 | |||
| Yes | 67 (81.7) | 36 (85.7) | 31 (77.5) | |
| No | 15 (18.3) | 6 (14.3) | 9 (22.5) | |
| The time of received RT | ||||
| Before IT+TT (RT → IT + TT) | 14 (33.3) | ‐ | ||
| After IT+TT (IT+TT → RT) | 9 (21.4) | ‐ | ||
| Concurrent (RT − IT + TT) | 19 (45.2) | ‐ | ||
| PD‐1 monoclonal antibody | ||||
| Sintilimab | 64 (78.0) | 30 (71.4) | 34 (85.0) | ‐ |
| Nivolumab | 3 (3.7) | 1 (2.4) | 2 (5.0) | ‐ |
| Camrelizumab | 4 (4.9) | 4 (9.5) | 0 (0.0) | ‐ |
| Pembrolizumab | 5 (6.1) | 5 (11.9) | 0 (0.0) | ‐ |
| Tislelizumab | 2 (2.4) | 1 (2.4) | 1 (2.5) | ‐ |
| Toripalimab | 4 (4.9) | 1 (2.4) | 3 (7.5) | ‐ |
| Targeting drugs | ||||
| Fruquintinib | 68 (82.9) | 33 (78.6) | 35 (87.5) | 0.28 a |
| Regorafenib | 14 (17.1) | 9 (21.4) | 5 (12.5) | |
| Gene mutation status b | ||||
| RAS wild | 29 (43.3) | 16 (48.5) | 13 (38.2) | 0.40 |
| RAS mutant | 38 (56.7) | 17 (51.5) | 21 (61.8) | |
| Lines of previous systemic therapy | ||||
| 2 line | 54 (65.9) | 25 (59.5) | 29 (72.5) | 0.22 |
| ≥3 lines | 28 (34.1) | 17 (40.5) | 11 (27.5) | |
| Cycles of TT + IT, median(range) | 4 (2–26) | 5 (2–20) | 4 (2–26) | 0.70 |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; IT, immunotherapy; PD‐1, programmed cell death 1; RT, radiotherapy; TT, targeted therapy.
a
Fisher's exact test.
b
Some data missing.